---
figid: PMC11393989__cells-13-01493-g001
figtitle: Molecular and cellular mechanisms of TGFB signaling pathway in GO
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11393989
filename: cells-13-01493-g001.jpg
figlink: /pmc/articles/PMC11393989/figure/F1/
number: F1
caption: Molecular and cellular mechanisms of TGF-β signaling pathway in GO. TGF-β
  exerts its multifaceted effects on fibrosis and inflammation through both canonical
  and non-canonical signaling pathways. It binds to TGFR2, subsequently activating
  TGFR1. In the canonical pathway, TGFR1 phosphorylates Smad2 and Smad3, enabling
  their complex formation with Smad4. This complex then translocates to the nucleus,
  initiating transcription of fibrogenic genes. In non-canonical signaling pathways,
  TGF-β promotes fibrosis and ECM deposition by activating mitogen-activated protein
  kinase (MAPK) pathways, phosphoinositide 3-kinase (PI3K) pathways, RhoA-GTPase pathways,
  Wnt/β-catenin pathways, and NOX4 pathways. In the MAPK pathways, phosphorylated
  p38/JNK also interacts with the canonical pathway by activating Smad2 and Smad3,
  c-Jun, and AP-1. Additionally, in the Wnt/β-catenin pathway, Wnt ligands bind to
  the FZD and LRP5/6 receptors, leading to increased levels of β-catenin. β-catenin
  then translocates to the nucleus to induce target gene expression. The blue arrow
  indicates an activating effect, while the red T-bar signifies an inhibitory effect
papertitle: A Review of Pathophysiology and Therapeutic Strategies Targeting TGF-β
  in Graves’ Ophthalmopathy
reftext: Hsin-Ho Chang, et al. Cells. 2024 Sep;13(17).
year: '2024'
doi: 10.3390/cells13171493
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: Graves’ ophthalmopathy (GO) | transforming growth factor-β (TGF-β) | orbital
  fibrosis | extracellular matrix (ECM) | orbital fibroblast
automl_pathway: 0.921814
figid_alias: PMC11393989__F1
figtype: Figure
redirect_from: /figures/PMC11393989__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11393989__cells-13-01493-g001.html
  '@type': Dataset
  description: Molecular and cellular mechanisms of TGF-β signaling pathway in GO.
    TGF-β exerts its multifaceted effects on fibrosis and inflammation through both
    canonical and non-canonical signaling pathways. It binds to TGFR2, subsequently
    activating TGFR1. In the canonical pathway, TGFR1 phosphorylates Smad2 and Smad3,
    enabling their complex formation with Smad4. This complex then translocates to
    the nucleus, initiating transcription of fibrogenic genes. In non-canonical signaling
    pathways, TGF-β promotes fibrosis and ECM deposition by activating mitogen-activated
    protein kinase (MAPK) pathways, phosphoinositide 3-kinase (PI3K) pathways, RhoA-GTPase
    pathways, Wnt/β-catenin pathways, and NOX4 pathways. In the MAPK pathways, phosphorylated
    p38/JNK also interacts with the canonical pathway by activating Smad2 and Smad3,
    c-Jun, and AP-1. Additionally, in the Wnt/β-catenin pathway, Wnt ligands bind
    to the FZD and LRP5/6 receptors, leading to increased levels of β-catenin. β-catenin
    then translocates to the nucleus to induce target gene expression. The blue arrow
    indicates an activating effect, while the red T-bar signifies an inhibitory effect
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - XK
  - NLRP1
  - TGFB1
  - TGFB2
  - TGFB3
  - LRP5
  - LRP6
  - RHOA
  - DECR1
  - RHCE
  - FIP1L1
  - SMAD7
  - FZD4
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - ARHGAP1
  - SOX9
  - DVL1
  - DVL1P1
  - SMAD2
  - ROCK1
  - ROCK2
  - MAP3K1
  - MAP3K2
  - MAP3K3
  - MAP3K4
  - MAP3K5
  - MAP3K6
  - MAP3K7
  - MAP3K8
  - MAP3K9
  - MAP3K10
  - MAP3K11
  - MAP3K12
  - MAP3K13
  - MAP3K14
  - MAP3K15
  - MAP3K19
  - MAP3K20
  - MAP3K21
  - ARAF
  - BRAF
  - RAF1
  - TAOK1
  - TAOK2
  - TAOK3
  - SMAD3
  - CCN2
  - MAP2K3
  - MAP2K4
  - MAP2K5
  - MAP2K6
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - SMAD4
  - MAPK8
  - MAPK9
  - MAPK10
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - NOX4
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - ACTA1
  - TIMP1
  - Antioxidants
  - NADP+
  - Pirfenidone
  - ROS
  - Simvastatin
  - Nucleus
---
